ORIC Pharmaceuticals Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ null, null, 7.22, 66.12, 292.12 ], "ebit_estimate": [ -169.82, -198.89, -228.11, -252.57, -121.74 ], "ebitda_estimate": [ -170.79, -203.13, -223.35, -339.83, -255.46 ], "net_income_estimate": [ -156.57, -186.22, -215.03, -241.26, -108.48 ], "per_share_eps_estimate": [ -1.47, -1.64, -1.81, -1.77, -0.67 ], "eps_nri_estimate": [ -1.47, -1.61, -1.71, -1.76, -0.66 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null ], "pretax_income_estimate": [ -156.13, -186.65, -207.23, -232.31, -76.3 ], "operating_cash_flow_per_share_estimate": [ -1.01, -1.11, -1.66, null, null ], "roa_estimate": [ -39.2, -52.6, null, null, null ], "roe_estimate": [ -43.94, -51.4, -30.74, null, null ], "gross_margin_estimate": [ null, null, 77, 86, 92 ], "operating_cash_flow_estimate": [ -106.53, -117.08, -175.09, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -5.63, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -7.62, "future_eps_nri_estimate_growth": -5.63, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -16.87, "future_ebitda_estimate_growth": -16.61, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -18.48, "future_pretax_income_estimate_growth": -17.23, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ null, null, null, null, null, null, null ], "ebit_estimate": [ -40.99, -43.5, -45.7, -48.08, -50.24, -51.69, -53.08 ], "ebitda_estimate": [ -41.25, -43.56, -46.4, -59, -61.95, -65.05, -68.3 ], "net_income_estimate": [ -38.14, -40.56, -42.87, -45.49, -48.04, -49.27, -50.79 ], "per_share_eps_estimate": [ -0.36, -0.37, -0.39, -0.38, -0.4, -0.4, -0.41 ], "eps_nri_estimate": [ -0.36, -0.37, -0.39, -0.38, -0.4, -0.41, -0.41 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -38.37, -40.2, -42.76, -48.28, -51.21, -53.02, -55.68 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ -40.15, -44.71, -49.93, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -5.63, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -7.62, "future_eps_nri_estimate_growth": -5.63, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -16.87, "future_ebitda_estimate_growth": -16.61, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -18.48, "future_pretax_income_estimate_growth": -17.23, "future_book_value_per_share_estimate_growth": null, "future_roa_estimate_growth": null, "future_roe_estimate_growth": null, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }